 "Bal Pharma enters into OTC segment with eye care product")
Bal Pharma Ltd has ventured into over-the-counter (OTC) market with the launch of Eye Spa, an eye care product, in Bangalore. This is the first among the series of OTC products that the company has lined up for launching in the market through its subsidiary, Lifezen Healthcare Pvt Ltd.
"Eye Spa is an unique product which soothes and rejuvenates the tired eyes, due to their continous exposure to dust, TV/computer screen, air conditioning and other modern lifestyle disorders. Bangalore market is choosen for the launch of Eye Spa as majority of its population are exposed to above said lifestyle disorders," said Bal Pharma in a press release.
The company plans to roll out its products in other south Indian markets shortly, before its pan India launch.
Shailesh Siroya, managing director, Bal Pharma, said, "OTC market in India is at its infancy right now and the company has the first mover advantage to test, explore and build its products in Indian market, before other players enter. Manufacturing might of the company coupled with its fully integrated R&D facility and a considerable field force will ensure that the OTC products will reach its end users fast and gain their acceptance."
"Eye Spa is an unique product which soothes and rejuvenates the tired eyes, due to their continous exposure to dust, TV/computer screen, air conditioning and other modern lifestyle disorders. Bangalore market is choosen for the launch of Eye Spa as majority of its population are exposed to above said lifestyle disorders," said Bal Pharma in a press release.
The company plans to roll out its products in other south Indian markets shortly, before its pan India launch.
Shailesh Siroya, managing director, Bal Pharma, said, "OTC market in India is at its infancy right now and the company has the first mover advantage to test, explore and build its products in Indian market, before other players enter. Manufacturing might of the company coupled with its fully integrated R&D facility and a considerable field force will ensure that the OTC products will reach its end users fast and gain their acceptance."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%